Skip to content

CONMED CNMD Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Boston Scientific logo
Boston ScientificBSX
IAR
Integra LifeSciencesIART
STERIS logo
STERISSTE
Intuitive Surgical logo
Intuitive SurgicalISRG

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.07B-34.0%
Enterprise value$1.89B-23.5%
P/E19.4×+5.8×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's preferred stock, shares authorized?
CONMED (CNMD) reported preferred stock, shares authorized of $500K in Q1 2026.
How has CONMED's preferred stock, shares authorized changed year-over-year?
CONMED's preferred stock, shares authorized decreased by 0.0% year-over-year, from $500K to $500K.
What is the long-term trend for CONMED's preferred stock, shares authorized?
Over 5 years (2020 to 2025), CONMED's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $500K to $500K.